OPRX vs. EGHT, PMTS, ABSI, ZH, SHAP, RGP, MPLN, RMNI, AHG, and NUTX
Should you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include 8X8 (EGHT), CPI Card Group (PMTS), Absci (ABSI), Zhihu (ZH), Spree Acquisition Corp. 1 (SHAP), Resources Connection (RGP), MultiPlan (MPLN), Rimini Street (RMNI), Akso Health Group (AHG), and Nutex Health (NUTX). These companies are all part of the "business services" industry.
OptimizeRx vs.
8X8 (NASDAQ:EGHT) and OptimizeRx (NASDAQ:OPRX) are both small-cap computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, dividends, media sentiment, risk and earnings.
8X8 has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.
8X8 presently has a consensus target price of $2.87, suggesting a potential upside of 9.18%. OptimizeRx has a consensus target price of $9.06, suggesting a potential upside of 67.51%. Given OptimizeRx's stronger consensus rating and higher possible upside, analysts clearly believe OptimizeRx is more favorable than 8X8.
In the previous week, 8X8 had 8 more articles in the media than OptimizeRx. MarketBeat recorded 8 mentions for 8X8 and 0 mentions for OptimizeRx. 8X8's average media sentiment score of 0.56 beat OptimizeRx's score of 0.00 indicating that 8X8 is being referred to more favorably in the media.
OptimizeRx has lower revenue, but higher earnings than 8X8. 8X8 is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.
94.0% of 8X8 shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 1.2% of 8X8 shares are owned by company insiders. Comparatively, 6.1% of OptimizeRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
8X8 has a net margin of -9.68% compared to OptimizeRx's net margin of -27.41%. OptimizeRx's return on equity of -4.92% beat 8X8's return on equity.
OptimizeRx received 128 more outperform votes than 8X8 when rated by MarketBeat users. Likewise, 63.64% of users gave OptimizeRx an outperform vote while only 50.98% of users gave 8X8 an outperform vote.
Summary
OptimizeRx beats 8X8 on 10 of the 18 factors compared between the two stocks.
Get OptimizeRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptimizeRx Competitors List
Related Companies and Tools
This page (NASDAQ:OPRX) was last updated on 1/21/2025 by MarketBeat.com Staff
Free OPRX Stock Alerts